Chronic Intestinal Pseudo-Obstruction (CIPO)
- Home
- Solutions
- By Diseases
- Intestinal Diseases
- Chronic Intestinal Pseudo-Obstruction (CIPO)
Chronic intestinal pseudo-obstruction (CIPO) is an unusual gastroenteric disease stemming from dysfunction of gut motility and is defined by obstruction phenotypic expression both symptoms and radiologically without any occlusive (mechanical) lesions. As a research service provider, Protheragen is focused on offering a complete range of services for the therapeutic development of CIPO. From drug discovery to preclinical research stages, we are committed to advancing the understanding and therapy of this challenging gastrointestinal disorder.
Chronic intestinal pseudo-obstruction (CIPO) is an uncommon and very severe illness that obstructs one's intestines but lacks anatomical evidence to support such obstruction. It impacts all segments of the gastrointestinal tract, mostly the small intestines and the colon. The disorder's prevalence rate is speculated to be one and 0.80 cases per 100,000 for males and females respectively.
Fig.1 Imaging findings of CIPO individuals. (Tayama, S., et al., 2024)A few ailments are linked with CIPO which include Hirschsprung's disease, mitochondrial neurogastrointestinal encephalomyopathy, or even paraneoplastic CIPO. In the other instances, CIPO appears to be 'primary' or 'idiopathic', but two subcategories can be distinguished among them: those with CIPO resulting from a sporadic abnormal autoimmune/inflammatory abnormality aimed at neural or muscular structures of the intestine, and those with an inherited or de novo genetic defect in the muscle, neural, or interstitial cell function.
Fig.2 Diagnostic flow chart in individuals with CIPO. (Basilisco, G., et al., 2024)
| Drug Names | Mechanism of Action | Targets | NCT Number | Research Phase |
| Rifaximin | Prevents protein biosynthesis in bacteria by binding to RpoB. | Bacterial RNAP | NCT04118699 | Phase II |
| Velusetrag | An active and selective 5-HT4 receptor agonist that exhibits a marked efficacy. | 5-HT4 receptor | NCT05724069 | Phase II |
| Fecal microbiota transplantation (FMT) | Restores homeostasis of the intestinal microbial community structure that had been disturbed. | / | NCT02731183 | Phase I |
Disclaimer: Protheragen focuses on providing preclinical research services. This table is for information exchange purposes only. This table is not a treatment plan recommendation. For guidance on treatment options, please visit a regular hospital.
Every project our team takes on will tailored solutions that will provide trustworthy results as our knowledgeable scientists and researchers have a wealth of experience and expertise in therapeutic development. The process of creating new therapies for CIPO can be simplified with our diagnostic, therapeutic, and disease model development services as we provide one-stop solutions.
Constructing animal models for CIPO is essential for understanding its pathophysiology as well as finding a suitable therapy. Our company provides various animal model development services that serve as tools for studying the mechanisms of the disorder and testing possible therapy interventions.
Genetically Engineering Models
Animal models that are genetically altered enhance understanding of the disorder's etiology and develop potential therapy targets by creating specific genetic modifications associated with CIPO.
Optional models: PrP-SCA7-92Q transgenic model, SRF mutation model, IP3R1 knockout model, etc.
Protheragen assesses the efficacy and safety of new drug candidates through extensive pharmacokinetic analysis and biosafety evaluation services. Your project will be meticulously supported by our interdisciplinary team that incorporates advanced technology and professional know-how to achieve seamless collaboration. If you are interested in our services, do not hesitate otherwise to contact us.
References
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.